Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist—Cligosiban—in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects

The Journal of Sexual Medicine - Tập 15 - Trang 1547-1557 - 2018
Ian H. Osterloh1, Gary J. Muirhead1, Stefan Sultana2,3, Steven Whaley4, Frans van den Berg4, George Atiee5
1Ixchelsis Ltd, Sandwich, United Kingdom
2Pfizer Global Research and Development, Sandwich, United Kingdom
3AstraZeneca, Cambridge, United Kingdom
4Hammersmith Medicines Research Ltd, London, United Kingdom
5Worldwide Clinical Trials, Early Phase Services LLC, San Antonio, Texas, USA

Tóm tắt

Abstract Introduction Cligosiban is a selective oxytocin receptor antagonist being developed for the treatment of premature ejaculation (PE). Aim Three clinical studies investigated the pharmacokinetics (including effect of food and formulation), central penetration, safety, and tolerability of single oral doses of cligosiban in healthy subjects. Methods Study 1 was a double-blind, randomized, placebo-controlled, crossover design in 3 cohorts of 10 subjects each. Single doses of 0.3–2,400 mg cligosiban were administered as aqueous solutions or dispersions under fasting and fed (800 mg only) conditions. Studies 2 and 3 were open-label, randomized, crossover designs in 12 subjects each. Study 2 investigated 800 mg cligosiban administered as capsules and aqueous dispersion under fasting conditions, and capsules under fed conditions. Study 3 investigated 1,600 mg cligosiban administered as caplets and aqueous dispersion under fasting conditions, and caplets under fed conditions. Main Outcome Measures Blood sampling for cligosiban assay and safety assessments were conducted throughout all studies. Cerebrospinal fluid (CSF) samples for cligosiban assay were collected in study 2. Results Cligosiban was rapidly absorbed under fasting conditions with peak concentrations generally occurring within 1–2 hours post-dose regardless of formulation. Maximum observed plasma concentration (Cmax) and area under the concentration time curve extrapolated to infinity (AUC0-∞) increased approximately dose-proportionally from 0.3–10 mg, but sub-proportionally from 30–2,400 mg. Cligosiban exposure was similar when administered as a dispersion or capsule (800 mg) under fasted conditions, but higher (87% increase) when administered as a caplet compared to the dispersion (1,600 mg). Food decreased the rate of absorption for all 3 formulations (median time to Cmax 3–6 hours compared to 1–2 hours fasted) but increased the extent of absorption (Cmax and AUC0-∞ increased by 75–149% and 33–49%, respectively). Cligosiban was detected in CSF at concentrations approximately 40% of unbound plasma concentrations. Cligosiban was well tolerated at all doses. Clinical Implications Cligosiban is well tolerated over a wide dose range, and has the pharmacokinetic properties to be taken as required prior to sexual intercourse in men with PE and to antagonize the oxytocin receptor in the brain and spinal cord. Strengths & Limitations Three controlled trials show similar toleration and pharmacokinetic data. Cligosiban in CSF indicates its likely presence in all central nervous system tissue. These data need to be investigated and confirmed in multiple-dose studies prior to investigation in phase-II studies in men with PE. Conclusion Cligosiban had a good safety/tolerability profile at doses predicted to be therapeutic or supra-therapeutic and a pharmacokinetic profile appropriate for “as-needed” dosing for men with PE.

Tài liệu tham khảo

International Nonproprietary Names for Pharmaceutical Substances (INN) WHO Drug Information 2017 31;4:655–6 Romero, 2000, An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue, Am J Obstet Gynecol, 182, 1173, 10.1067/mob.2000.95834 Tournaye, 2017, A placebo-controlled, randomized, double-blind study of pregnancy and live birth rates after single oral administration of a novel oxytocin antagonist, nolasiban, prior to embryo transfer, Hum Reprod, 32, i12 Assinder, 2008, Oxytocin increases 5a-reductase activity of human prostate epithelial cells, but not stromal cells, Prostate, 68, 115, 10.1002/pros.20671 Nicholson, 1995, Oxytocin and prostatic function, Adv Exp Med Biol, 395, 529 Xu, 2017, Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway, Clin Sci (Lond), 131, 595, 10.1042/CS20170030 Whittington, 2007, The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate, Prostate, 67, 1132, 10.1002/pros.20612 Zhong, 2010, Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway, Mol Cancer Res, 8, 1164, 10.1158/1541-7786.MCR-09-0329 Brown, 2010, Triazole oxytocin antagonists: identification of an aryloxyazetidine replacement for a biaryl substituent, Bioorg Med Chem Lett, 20, 516, 10.1016/j.bmcl.2009.11.097 McMahon, 2008, An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation, J Sex Med, 5, 1590, 10.1111/j.1743-6109.2008.00901.x Byers, 2003, Premature or rapid ejaculation: heterosexual couples’ perceptions of men’s ejaculatory behavior, Arch Sex Behav, 32, 261, 10.1023/A:1023417718557 Rosen, 2008, Impact of premature ejaculation: the psychological, quality of life, and sexual relationship consequences, J Sex Med, 5, 1296, 10.1111/j.1743-6109.2008.00825.x Priligy summary of product characteristics Wayman, Cligosiban, a novel brain penetrant selective oxytocin receptor antagonist, inhibits ejaculatory physiology in rodents, J Sex Med submitted Murphy, 1987, Changes in oxytocin and vasopressin secretion during sexual activity in men, J Clin Endocrinol Metab, 65, 738, 10.1210/jcem-65-4-738 Carmichael, 1987, Plasma oxytocin increases in the human sexual response, J Clin Endocrinol Metab, 64, 27, 10.1210/jcem-64-1-27 Gimpl, 2001, The oxytocin receptor system: structure, function and regulation, Physiol Rev, 81, 629, 10.1152/physrev.2001.81.2.629 Clément, 2008, Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OHDPAT) in anaesthetized rats, Br J Pharmacol, 154, 1150, 10.1038/bjp.2008.176 Witt, 1994, Increased Fos expression in oxytocin neurons following masculine sexual behavior, J Neuroendocrinol, 6, 13, 10.1111/j.1365-2826.1994.tb00549.x Gil, 2011, Oxytocin in the preoptic area facilitates male sexual behavior in the rat, Horm Behav, 59, 435, 10.1016/j.yhbeh.2010.12.012 Wayman, 2009, Oxytocin receptor gene deleted mice display disrupted sexual function—increased ejaculatory latency in males, and abolishment of lordosis in females, J Sex Med, 6, 11 Osterloh, 2017, The pharmacological profile of IX-01, a selective oxytocin receptor antagonist being developed to treat men with premature ejaculation, J Sex Med, 14, e117, 10.1016/j.jsxm.2017.03.101 US Food and Drug Administration. Guidance for industry, 2002, Food-effect bioavailability and fed bioequivalence studies Shinghal, 2013, Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study, J Sex Med, 10, 2506, 10.1111/jsm.12272 Clément, 2013, Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action, Br J Pharmacol, 169, 1477, 10.1111/bph.12198 Gupta, 2008, Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1A receptors and not oxytocin receptors, Br J Pharmacol, 155, 118, 10.1038/bjp.2008.226
Thông tin
Thông tin xuất bản

The Journal of Sexual Medicine

Tập 15

1547-1557

Thông tin tác giả